These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 24983631)

  • 1. The rational design of specific peptide inhibitor against p38α MAPK at allosteric-site: a therapeutic modality for HNSCC.
    Gill K; Nigam L; Singh R; Kumar S; Subbarao N; Chauhan SS; Dey S
    PLoS One; 2014; 9(7):e101525. PubMed ID: 24983631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of peptide inhibitor as a therapeutic agent against head and neck squamous cell carcinoma (HNSCC) targeting p38alpha MAP kinase.
    Gill K; Singh AK; Kapoor V; Nigam L; Kumar R; Holla P; Das SN; Yadav S; Subbarao N; Mohanti BK; Dey S
    Biochim Biophys Acta; 2013 Mar; 1830(3):2763-9. PubMed ID: 23238519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic Significance of p38 Isoforms (p38α, p38β, p38γ, p38δ) in Head and Neck Squamous Cell Carcinoma: Comparative Serum Level Evaluation and Design of Novel Peptide Inhibitor Targeting the Same.
    Sahu V; Nigam L; Agnihotri V; Gupta A; Shekhar S; Subbarao N; Bhaskar S; Dey S
    Cancer Res Treat; 2019 Jan; 51(1):313-325. PubMed ID: 29747487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human p38α mitogen-activated protein kinase in the Asp168-Phe169-Gly170-in (DFG-in) state can bind allosteric inhibitor Doramapimod.
    Suplatov D; Kopylov K; Sharapova Y; Švedas V
    J Biomol Struct Dyn; 2019 May; 37(8):2049-2060. PubMed ID: 29749295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular dynamics simulation and free energy calculation studies of the binding mechanism of allosteric inhibitors with p38α MAP kinase.
    Yang Y; Shen Y; Liu H; Yao X
    J Chem Inf Model; 2011 Dec; 51(12):3235-46. PubMed ID: 22097958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of an allosteric and Smad3-selective inhibitor of p38αMAPK using a substrate-based approach.
    Nagao H; Kitagawa D; Nakajima F; Sawa M; Kinoshita T
    Bioorg Med Chem Lett; 2021 Jul; 43():128056. PubMed ID: 33892104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a Novel Inhibitory Allosteric Site in p38α.
    Gomez-Gutierrez P; Campos PM; Vega M; Perez JJ
    PLoS One; 2016; 11(11):e0167379. PubMed ID: 27898710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A small-molecule mimic of a peptide docking motif inhibits the protein kinase PDK1.
    Rettenmaier TJ; Sadowsky JD; Thomsen ND; Chen SC; Doak AK; Arkin MR; Wells JA
    Proc Natl Acad Sci U S A; 2014 Dec; 111(52):18590-5. PubMed ID: 25518860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3D-QSAR and molecular docking studies on fused pyrazoles as p38α mitogen-activated protein kinase inhibitors.
    Lan P; Huang ZJ; Sun JR; Chen WM
    Int J Mol Sci; 2010 Sep; 11(9):3357-74. PubMed ID: 20957100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p38α MAPK and Type I Inhibitors: Binding Site Analysis and Use of Target Ensembles in Virtual Screening.
    Astolfi A; Iraci N; Sabatini S; Barreca ML; Cecchetti V
    Molecules; 2015 Aug; 20(9):15842-61. PubMed ID: 26334265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Comprehensive Structural Overview of p38α MAPK in Complex with Type I Inhibitors.
    Astolfi A; Iraci N; Manfroni G; Barreca ML; Cecchetti V
    ChemMedChem; 2015 Jun; 10(6):957-69. PubMed ID: 26012502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p38alpha and p38delta mitogen-activated protein kinase isoforms regulate invasion and growth of head and neck squamous carcinoma cells.
    Junttila MR; Ala-Aho R; Jokilehto T; Peltonen J; Kallajoki M; Grenman R; Jaakkola P; Westermarck J; Kähäri VM
    Oncogene; 2007 Aug; 26(36):5267-79. PubMed ID: 17334397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microglial p38α MAPK is a key regulator of proinflammatory cytokine up-regulation induced by toll-like receptor (TLR) ligands or beta-amyloid (Aβ).
    Bachstetter AD; Xing B; de Almeida L; Dimayuga ER; Watterson DM; Van Eldik LJ
    J Neuroinflammation; 2011 Jul; 8():79. PubMed ID: 21733175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutagenesis of p38alpha MAP kinase establishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-OUT state.
    Bukhtiyarova M; Karpusas M; Northrop K; Namboodiri HV; Springman EB
    Biochemistry; 2007 May; 46(19):5687-96. PubMed ID: 17441692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, Synthesis, and Molecular Docking of Novel Miscellaneous Chalcones as p38α Mitogen-Activated Protein Kinase Inhibitors.
    Zeid MM; El-Badry OM; Elmeligie S; Hassan RA
    Chem Biodivers; 2024 Apr; 21(4):e202400077. PubMed ID: 38359316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, biological evaluation, and docking studies of novel (imidazol-5-yl)pyrimidine-based derivatives as dual BRAF
    Ali EMH; El-Telbany RFA; Abdel-Maksoud MS; Ammar UM; Mersal KI; Zaraei SO; El-Gamal MI; Choi SI; Lee KT; Kim HK; Lee KH; Oh CH
    Eur J Med Chem; 2021 Apr; 215():113277. PubMed ID: 33601311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of p38α in peripheral blood mononuclear cells (PBMC): a potential blood protein marker of head and neck squamous cell carcinoma.
    Gill K; Kumar R; Mohanti BK; Dey S
    Clin Transl Oncol; 2013 Nov; 15(11):969-73. PubMed ID: 23553334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification of p38αMAP kinase: a prognostic marker in HNSCC with respect to radiation therapy.
    Gill K; Mohanti BK; Ashraf MS; Singh AK; Dey S
    Clin Chim Acta; 2012 Jan; 413(1-2):219-25. PubMed ID: 21982916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insights into MAPK p38alpha DFG flip mechanism by accelerated molecular dynamics.
    Filomia F; De Rienzo F; Menziani MC
    Bioorg Med Chem; 2010 Sep; 18(18):6805-12. PubMed ID: 20724167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3,4-Diaryl-isoxazoles and -imidazoles as potent dual inhibitors of p38alpha mitogen activated protein kinase and casein kinase 1delta.
    Peifer C; Abadleh M; Bischof J; Hauser D; Schattel V; Hirner H; Knippschild U; Laufer S
    J Med Chem; 2009 Dec; 52(23):7618-30. PubMed ID: 19591487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.